Annual shareholder meetings

Explore recordings and documents from the meetings

7 May 2026

The Annual General Meeting took place on 7 May 2026, in Kaiseraugst, Switzerland.

Annual General Meetings (EN) 

×

Annual General Meetings (DE) 

×

Annual General Meetings (NL) 

×

Annual General Meetings (FR) 

×

Downloads for the AGM 2026

6 May 2025

The Annual General Meeting took place on 6 May 2025, in Kaiseraugst, Switzerland.

Annual General Meetings (EN) 

×

Annual General Meetings (DE) 

×

Annual General Meetings (NL) 

×

Annual General Meetings (FR) 

×

Downloads for the AGM 2025

Agenda item 1.1
Integrated Annual Report 2024
Agenda item 1.2
Sustainability Report 2024 (Extract from the IAR 2024)
Agenda item 1.3
Compensation Report 2024 (Extract from the Integrated Annual Report 2024)
Agenda item 8
Articles of Association (with proposed changes highlighted in red)

Articles of Association (with proposed changes)

7 May 2024

The Annual General Meeting of DSM-Firmenich AG took place on 7 May 2024 at the company’s head offices at Wurmisberg 576, 4303 Kaiseraugst, Switzerland. All resolutions on the agenda were approved by the shareholders.

Annual General Meetings (EN) 

×

Annual General Meetings (DE) 

×

Annual General Meetings (NL) 

×

Annual General Meetings (FR) 

×

Downloads for the AGM 2024

29 June 2023

The extraordinary general meeting of shareholders was held on June 29, 2023 at the company offices at Wurmisweg 576, 4303 Kaiseraugst, Switzerland. All resolutions on the agenda were approved by the shareholders.

The shareholders or shareholder representatives voted on 197,464,498 shares or 74.45% of the issued share capital entitled to vote. Number of votes per share is 1 and the number of outstanding shares on 29 June 2023, the date of the meeting, was 265,217,171.

EGM (EN)

×

EGM (DE)

×

EGM (NL)

×

EGM (FR)

×

Downloads for the EGM 2023

Agenda item 1

Interim Financial Statements  

Agenda item 3

Remuneration at dsm-firmenich

Statement on BoD and Exco remuneration (ENG) 

Statement on BoD and Exco remuneration (NL) 

Agenda item 4

Articles of association (with proposed amendments highlighted)

Article of association (with proposed amendments)

Agenda item 1:

Approval of the stand-alone interim financial statements of DSM-Firmenich AG for the period from 1 January 2023 to 8 May 2023

 ForAgainstAbstain

Total

Votes

195,384,208

1,200,493

879,797

197,464,498

%

98.95%

0.61%

0.45%

 
Agenda item 2:

Dividend / Distribution of Capital Contribution Reserves

 ForAgainstAbstain

Total

Votes

197,445,780

8,293

10,425

197,464,498

%

99.99%

0.00%

0.01%

 
Agenda item 3.1

Approval of remuneration for the Board of Directors

 ForAgainstAbstain

Total

Votes

195,384,208

4,485,119

1,076,031

197,464,498

%

97.18%

2.27%

0.54%

 
Agenda item 3.2

Approval of the remuneration of the Executive Committee

 ForAgainstAbstain

Total

Votes

191,489,400

4,476,258

1,498,840

197,464,498

%

96.97%

2.27%

0.76%

 
Agenda item 4.1

Approval of certain important transactions by shareholders

 ForAgainstAbstain

Total

Votes

185,937,469

3,530,633

7,996,396

97,464,498

%

94.16%

1.79%

4.05%

 
Agenda item 4.2

Possibility of the Board of Directors to request custodians to disclose the identity of shareholders and beneficial owners

 ForAgainstAbstain

Total

Votes

184,157,906

3,790,079

9,516,513

197,464,498

%

93.26%

1.92%

4.82%

 

Contact Investor Relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.

Explore more
  • Corporate governance

    We are fully committed to good corporate governance. Our principles and rules on corporate governance are laid down in the articles of association and the organizational regulations, among other documents.

  • Sustainability

    Sustainability is fundamental to how dsm-firmenich brings progress to life – for people and planet.

  • Investors

    Through science and innovation, we are creating a world of potential for investors.

Stay up to date

Be the first to know about key news as we continue shaping the future and bringing progress to life.